

PERSONAL INFORMATION **Shai Izraeli****WORK EXPERIENCE**

-
- 2014–Present **Chair of Hematological Malignancies**
Tel Aviv University, (Israel)
- 2011–Present **Full Professor of Pediatrics**
Tel Aviv University, (Israel)
- 2003–Present **Head, functional genomics and childhood leukemia research institute**
Sheba Medical Center, Tel Hashomer, Israel, (Israel)
- 2000–Present **Senior Physician**
Dpt Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Israel, (Israel)

EDUCATION AND TRAINING

-
- 1983–Present **M.D.**
Hebrew University, (Israel)
- 1993–Present **M.Sc.**
Tel-Aviv University, (Israel)
- 1993 **Pediatric Residency**
Beilinson Medical Center , Petach Tikva, Israel
- 1990 **Research Fellowhsip**
Children' Cancer Research Institute, Vienna, Austria
- 1996 **Fellowhip Pediatric Hemato-Oncology**
National Cancer Institute, Bethesda, Md, USA
- 2000 **Post-Doctoral Training**
National Cancer Institute, Bethesda, Md, USA

ADDITIONAL INFORMATION**Expertise** A. Personal statement.

I am a physician scientist that focuses on translational laboratory based research of hemato-oncology with a particular emphasis on childhood leukemia. Another major research interest is centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer. These two interests are merged in the study of leukemias associated with germline (Down Syndrome) and somatic trisomy 21. Several of our discoveries proved to be of general importance to children and adults with acute leukemias. These include the discovery of ERG as an important hematopoietic oncogene and the discoveries of unique activating JAK2 mutations and of mutational activation of the cytokine receptors to TSLP and interleukin 7 in acute lymphoblastic leukemias (ALL). These findings

have led to new diagnostic tests and clinical trials of ALL. Our more general cancer-aneuploidy and centrosomal biology research has been promoted by our discovery of STIL (previously named STIL), a gene disrupted in T-ALL, as a major centrosomal duplication factor in mammalian cells. We study how STIL is involved in development and cancer.

We have intensive international collaborations in both basic and clinical studies with scientists and clinicians in North America, Australia, Japan and Europe. I am the co-chair of the Israeli national study of childhood leukemias, I have been the chair of the Biology and Diagnosis committee of the international BFM, the largest international cooperative research group of childhood leukemias and I am an elected member of the Board of the European Hematology Association.

Publications

D. Publications

<http://scholar.google.at/citations?user=&hl=en>

1. Tal, N., C. Shochat, I. Geron, D. Bercovich, and S. Izraeli, Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. *Cell Mol Life Sci*, 2014. 71(3): p. 365-78.
2. Stary, J., M. Zimmermann, M. Campbell, L. Castillo, E. Dibar, S. Donska, A. Gonzalez, S. Izraeli, D. Janic, J. Jazbec, J. Konja, E. Kaiserova, J. Kowalczyk, G. Kovacs, C.K. Li, E. Magyarosy, A. Popa, B. Stark, Y. Jabali, J. Trka, O. Hrusak, H. Riehm, G. Masera, and M. Schrappe, Intensive chemotherapy for childhood acute
2
Prof Shai Izraeli October 2014
lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. *J Clin Oncol*, 2014. 32(3): p. 174-84.
3. Shochat, C., N. Tal, V. Gryshkova, Y. Birger, O.R. Bandapalli, G. Cazzaniga, N. Gershman, A.E. Kulozik, A. Biondi, M.R. Mansour, J.C. Twizere, M.U. Muckenthaler, N. Ben-Tal, S.N. Constantinescu, D. Bercovich, and S. Izraeli, Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. *Blood*, 2014. 10.1182/blood-2013-10-529685.
4. Roberts, I. and S. Izraeli, Haematopoietic development and leukaemia in Down syndrome. *Br J Haematol*, 2014. 10.1111/bjh.13096.
5. Mezei, G., M. Sudan, S. Izraeli, and L. Kheifets, Epidemiology of childhood leukemia in the presence and absence of Down syndrome. *Cancer Epidemiol*, 2014. 10.1016/j.canep.2014.07.006.
6. Meissner, B., T. Bartram, C. Eckert, J. Trka, R. Panzer-Grumayer, I. Hermanova, E. Ellinghaus, A. Franke, A. Moricke, A. Schrauder, A. Teigler-Schlegel, P. Dorge, A. von Stackelberg, G. Basso, C.R. Bartram, R. Kirschner-Schwabe, B. Bornhauser, J.P. Bourquin, G. Cazzaniga, J. Hauer, A. Attarbaschi, S. Izraeli, M. Zaliova, G. Cario, M. Zimmermann, S. Avigad, M. Sokalska-Duhme, M. Metzler, M. Schrappe, R. Koehler, G. Te Kronnie, and M. Stanulla, Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. *Hum Mol Genet*, 2014. 23(3): p. 590-601.
7. Lane, A.A., B. Chapuy, C.Y. Lin, T. Tivey, H. Li, E.C. Townsend, D. van Bodegom, T.A. Day, S.C. Wu, H. Liu, A. Yoda, G. Alexe, A.C. Schinzel, T.J. Sullivan, S. Malinge, J.E. Taylor, K. Stegmaier, J.D. Jaffe, M. Bustin, G. Te Kronnie, S. Izraeli, M.H. Harris, K.E. Stevenson, D. Neuberg, L.B. Silverman, S.E. Sallan, J.E. Bradner, W.C. Hahn, J.D. Crispino, D. Pellman, and D.M. Weinstock, Triplication of a 21q22 region contributes to B cell transformation through HMG1 overexpression and loss of histone H3 Lys27 trimethylation. *Nat Genet*, 2014. 46(6): p. 618-23.
8. Izraeli, S., A. Vora, C.M. Zwaan, and J. Whitlock, How I treat ALL in Down's syndrome: pathobiology and management. *Blood*, 2014. 123(1): p. 35-40.
9. Izraeli, S., C. Shochat, N. Tal, and I. Geron, Towards precision medicine in childhood leukemia - Insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia. *Cancer Lett*, 2014. 10.1016/j.canlet.2014.02.009.
10. Izraeli, S., Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises. *Curr Opin Hematol*, 2014. 21(4): p. 289-96.
11. Chapnik, E., N. Rivkin, A. Mildner, G. Beck, R. Pasvolsky, E. Metzli-Raz, Y. Birger, G. Amir, I. Tirosh, Z. Porat, L.L. Israel, E. Lellouche, S. Michaeli, J.P. Lellouche, S. Izraeli, S. Jung, and E. Hornstein, miR-142 orchestrates a network of actin cytoskeleton regulators during megakaryopoiesis. *Elife*, 2014. 10.7554/eLife.01964: p. e01964.
12. Buitenkamp, T.D., S. Izraeli, M. Zimmermann, E. Forestier, N.A. Heerema, M.M. van den Heuvel-Eibrink, R. Pieters, C.M. Korbijn, L.B. Silverman, K. Schmiegelow, D.C. Liang, K. Horibe, M. Arico, A. Biondi, G. Basso, K.R. Rabin, M. Schrappe, G. Cario, G. Mann, M. Morak, R. Panzer-Grumayer, V.

- Mondelaers, T. Lammens, H. Cave, B. Stark, I. Ganmore, A.V. Moorman, A. Vora, S.P. Hunger, C.H. Pui, C.G. Mullighan, A. Manabe, G. Escherich, J.R. Kowalczyk, J.A. Whitlock, and C.M. Zwaan, Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. *Blood*, 2014. 123(1): p. 70-7.
13. Bandapalli, O.R., S. Schuessle, J.B. Kunz, T. Rausch, A.M. Stutz, N. Tal, I. Geron, N. Gershman, S. Izraeli, J. Eilers, N. Vaezipour, R. Kirschner-Schwabe, J. Hof, A. von Stackelberg, M. Schrappe, M. Stanulla, M. Zimmermann, R. Koehler, S. Avigad, R. Handgretinger, V. Frisimantas, J.P. Bourquin, B. Bornhauser, J.O. Korb, M.U. Muckenthaler, and A.E. Kulozik, The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. *Haematologica*, 2014. 10.3324/haematol.2014.104992.
14. Auer, F., F. Ruschendorf, M. Gombert, P. Husemann, S. Ginzel, S. Izraeli, M. Harit, M. Weintraub, O.Y. Weinstein, I. Lerer, P. Stepensky, A. Borkhardt, and J. Hauer, Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>>A. *Leukemia*, 2014. 28(5): p. 1136-8.
15. Amartely, H., A. David, M. Lebediker, H. Benyamini, S. Izraeli, and A. Friedler, The STIL protein contains intrinsically disordered regions that mediate its protein-protein interactions. *Chem Commun (Camb)*, 2014. 50(40): p. 5245-7.
16. Yoshida, K., T. Toki, Y. Okuno, R. Kanezaki, Y. Shiraishi, A. Sato-Otsubo, M. Sanada, M.J. Park, K. Terui, H. Suzuki, A. Kon, Y. Nagata, Y. Sato, R. Wang, N. Shiba, K. Chiba, H. Tanaka, A. Hama, H. Muramatsu, D. Hasegawa, K. Nakamura, H. Kanegane, K. Tsukamoto, S. Adachi, K. Kawakami, K. Kato, R. Nishimura, S. Izraeli, Y. Hayashi, S. Miyano, S. Kojima, E. Ito, and S. Ogawa, The landscape of somatic mutations in Down syndrome-related myeloid disorders. *Nat Genet*, 2013. 45(11): p. 1293-9.
17. Meyer, C., J. Hofmann, T. Burmeister, D. Groger, T.S. Park, M. Emerenciano, M. Pombo de Oliveira, A. Renneville, P. Villarese, E. Macintyre, H. Cave, E. Clappier, K. Mass-Malo, J. Zuna, J. Trka, E. De Braekeleer, M. De Braekeleer, S.H. Oh, G. Tsaor, L. Fechina, V.H. van der Velden, J.J. van Dongen, E. Delabesse, R. Binato, M.L. Silva, A. Kustanovich, O. Aleinikova, M.H. Harris, T. Lund-Aho, V. Juvonen, O. Heidenreich, J. Vormoor, W.W. Choi, M. Jarosova, A. Kolenova, C. Bueno, P. Menendez, S. Wehner, C. Eckert, P. Talmant, S. Tondeur, E. Lippert, E. Launay, C. Henry, P. Ballerini, H. Lapillone, M.B. Callanan, J.M. Cayuela, C. Herbaux, G. Cazzaniga, 3
- Prof Shai Izraeli October 2014
- P.M. Kakadiya, S. Bohlander, M. Ahlmann, J.R. Choi, P. Gameiro, D.S. Lee, J. Krauter, P. Cornillet-Lefebvre, G. Te Kronnie, B.W. Schafer, S. Kubetzko, C.N. Alonso, U. Zur Stadt, R. Sutton, N.C. Venn, S. Izraeli, L. Trakhtenbrot, H.O. Madsen, P. Archer, J. Hancock, N. Cerveira, M.R. Teixeira, L. Lo Nigro, A. Moricke, M. Stanulla, M. Schrappe, L. Sedek, T. Szczepanski, C.M. Zwaan, E.A. Coenen, M.M. van den Heuvel-Eibrink, S. Strehl, M. Dworzak, R. Panzer-Grumayer, T. Dingermann, T. Klingebiel, and R. Marschalek, The MLL recombinome of acute leukemias in 2013. *Leukemia*, 2013. leu2013135 [pii] 10.1038/leu.2013.135.
18. Goldberg, L., M.R. Tijssen, Y. Birger, R.L. Hannah, S.J. Kinston, J. Schutte, D. Beck, K. Knezevic, G. Schiby, J. Jacob-Hirsch, A. Biran, Y. Kloog, G. Marcucci, C.D. Bloomfield, P.D. Aplan, J.E. Pimanda, B. Gottgens, and S. Izraeli, Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. *Blood*, 2013. 122(15): p. 2694-703.
19. Castiel, A., L. Visochek, L. Mittelman, Y. Zilberstein, F. Dantzer, S. Izraeli, and M. Cohen-Armon, Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells. *J Vis Exp*, 2013. 10.3791/50568(78): p. e50568.
20. Birger, Y., L. Goldberg, T.M. Chlon, B. Goldenson, I. Muler, G. Schiby, J. Jacob-Hirsch, G. Rechavi, J.D. Crispino, and S. Izraeli, Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. *Blood*, 2013. 122(6): p. 988-98.
21. Wen, Q., B. Goldenson, S.J. Silver, M. Schenone, V. Dancik, Z. Huang, L.Z. Wang, T.A. Lewis, W.F. An, X. Li, M.A. Bray, C. Thiollier, L. Diebold, L. Gilles, M.S. Vokes, C.B. Moore, M. Bliss-Moreau, L. Verplank, N.J. Tolliday, R. Mishra, S. Vemula, J. Shi, L. Wei, R. Kapur, C.K. Lopez, B. Gerby, P. Ballerini, F. Pflumio, D.G. Gilliland, L. Goldberg, Y. Birger, S. Izraeli, A.S. Gamis, F.O. Smith, W.G. Woods, J. Taub, C.A. Scherer, J.E. Bradner, B.C. Goh, T. Mercher, A.E. Carpenter, R.J. Gould, P.A. Clemons, S.A. Carr, D.E. Root, S.L. Schreiber, A.M. Stern, and J.D. Crispino, Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. *Cell*, 2012. 150(3): p. 575-89.
22. Vulprecht, J., A. David, A. Tibelius, A. Castiel, G. Konotop, F. Liu, F. Bestvater, M.S. Raab, H. Zentgraf, S. Izraeli, and A. Kramer, STIL is required for centriole duplication in human cells. *J Cell Sci*, 2012. 125(Pt 5): p. 1353-62.
23. Shlush, L.I., N. Chapal-Ilani, R. Adar, N. Pery, Y. Maruvka, A. Spiro, R. Shouval, J.M. Rowe, M. Tzukerman, D. Bercovich, S. Izraeli, G. Marcucci, C.D. Bloomfield, T. Zuckerman, K. Skorecki, and E.

- Shapiro, Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. *Blood*, 2012. 120(3): p. 603-12.
24. Shaham, L., V. Binder, N. Gefen, A. Borkhardt, and S. Izraeli, MiR-125 in normal and malignant hematopoiesis. *Leukemia*, 2012. 26(9): p. 2011-8.
25. Palmi, C., E. Vendramini, D. Silvestri, G. Longinotti, D. Frison, G. Cario, C. Shochat, M. Stanulla, V. Rossi, A.M. Di Meglio, T. Villa, E. Giarin, G. Fazio, A. Leszl, M. Schrappe, G. Basso, A. Biondi, S. Izraeli, V. Conter, M.G. Valsecchi, G. Cazzaniga, and G. Te Kronnie, Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. *Leukemia*, 2012. 26(10): p. 2245-53.
26. Elhasid, R., T. Tohami, N. Moustafa-Hawash, J. Ben-Ezra, S. Izraeli, and D. Sayar, Spontaneous Remission of Childhood Acute Marrow Fibrosis and Megakaryoblastic Leukemia. *J Pediatr Hematol Oncol*, 2012. 10.1097/MPH.0b013e318257a172.
27. Birger, Y. and S. Izraeli, DYRK1A in Down syndrome: an oncogene or tumor suppressor? *J Clin Invest*, 2012. 122(3): p. 807-10.
28. Thoms, J.A., Y. Birger, S. Foster, K. Knezevic, Y. Kirschenbaum, V. Chandrakanthan, G. Jonquieres, D. Spensberger, J.W. Wong, S.H. Oram, S.J. Kinston, Y. Groner, R. Lock, K.L. MacKenzie, B. Gottgens, S. Izraeli, and J.E. Pimanda, ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. *Blood*, 2011. 117(26): p. 7079-89.
29. Shochat, C., N. Tal, O.R. Bandapalli, C. Palmi, I. Ganmore, G. Te Kronnie, G. Cario, G. Cazzaniga, A.E. Kulozik, M. Stanulla, M. Schrappe, A. Biondi, G. Basso, D. Bercovich, M.U. Muckenthaler, and S. Izraeli, Gain-of-function mutations in interleukin-7 receptor- $\{\alpha\}$ (IL7R) in childhood acute lymphoblastic leukemias. *J Exp Med*, 2011. 208(5): p. 901-8.
30. Ozery-Flato, M., C. Linhart, L. Trakhtenbrot, S. Izraeli, and R. Shamir, Large-scale analysis of chromosomal aberrations in cancer karyotypes reveals two distinct paths to aneuploidy. *Genome Biol*, 2011. 12(6): p. R61.
31. Castiel, A., L. Visochek, L. Mittelman, F. Dantzer, S. Izraeli, and M. Cohen-Armon, A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. *BMC Cancer*, 2011. 11: p. 412.
32. Castiel, A., M.M. Danieli, A. David, S. Moshkovitz, P.D. Aplan, I.R. Kirsch, M. Brandeis, A. Kramer, and S. Izraeli, The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr. *J Cell Sci*, 2011. 124(Pt 4): p. 532-9.
33. Blink, M., T.D. Buitenkamp, M.M. van den Heuvel-Eibrink, A.A. Danen-van Oorschot, V. de Haas, D. Reinhardt, J.H. Klusmann, M. Zimmermann, M. Devidas, A.J. Carroll, G. Basso, A. Pession, H. Hasle, R. Pieters, K.R. 4
- Prof Shai Izraeli October 2014
- Rabin, S. Izraeli, and C.M. Zwaan, Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. *Leukemia*, 2011. 25(8): p. 1365-8.
34. Stepensky, P., R. Brooks, E. Waldman, S. Revel-Vilk, S. Izraeli, I. Resnick, and M. Weintraub, A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. *Pediatr Blood Cancer*, 2010. 54(7): p. 1048-9.
35. Stark, B., R. Nirel, G. Avrahami, A. Abramov, D. Attias, A. Ballin, B. Bielgorai, Y. Burstein, H. Gavriel, R. Elhasid, J. Kapelushnik, D. Stoege, A. Toren, M. Wientraub, I. Yaniv, and S. Izraeli, Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. *Leukemia*, 2010. 24(2): p. 419-24.
36. Mejstrikova, E., E. Fronkova, T. Kalina, M. Omelka, D. Batinic, K. Dubravcic, K. Pospisilova, M. Vaskova, D. Luria, S.H. Cheng, M. Ng, Y. Leung, J. Kappelmayer, F. Kiss, S. Izraeli, B. Stark, M. Schrappe, J. Trka, J. Stary, and O. Hrusak, Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. *Pediatr Blood Cancer*, 2010. 54(1): p. 62-70.
37. Luria, D., E. Rosenthal, D. Steinberg, Y. Kodman, M. Safanaiev, N. Amariglio, S. Avigad, B. Stark, and S. Izraeli, Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. *Cytometry B Clin Cytom*, 2010. 78(6): p. 365-71.
38. Izraeli, S., Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? *Br J Haematol*, 2010. 151(2): p. 119-31.
39. Izraeli, S., Similar yet different. *Blood*, 2010. 116(7): p. 1019-20.
40. Hertzberg, L., E. Vendramini, I. Ganmore, G. Cazzaniga, M. Schmitz, J. Chalker, R. Shiloh, I. Iacobucci, C. Shochat, S. Zeligson, G. Cario, M. Stanulla, S. Strehl, L.J. Russell, C.J. Harrison, B.

- Bornhauser, A. Yoda, G. Rechavi, D. Bercovich, A. Borkhardt, H. Kempfski, G. te Kronnie, J.P. Bourquin, E. Domany, and S. Izraeli, Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood*, 2010. 115(5): p. 1006-17.
41. Harrison, C.J., O. Haas, J. Harbott, A. Biondi, M. Stanulla, J. Trka, and S. Izraeli, Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. *Br J Haematol*, 2010. 151(2): p. 132-42.
42. Gefen, N., V. Binder, M. Zaliova, Y. Linka, M. Morrow, A. Novosel, L. Edry, L. Hertzberg, N. Shomron, O. Williams, J. Trka, A. Borkhardt, and S. Izraeli, Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. *Leukemia*, 2010. 24(1): p. 89-96.
43. Cario, G., M. Zimmermann, R. Romey, S. Gesk, I. Vater, J. Harbott, A. Schrauder, A. Moericke, S. Izraeli, T. Akasaka, M.J. Dyer, R. Siebert, M. Schrappe, and M. Stanulla, Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. *Blood*, 2010. 115(26): p. 5393-7.
44. Bourquin, J.P. and S. Izraeli, Where can biology of childhood ALL be attacked by new compounds? *Cancer Treat Rev*, 2010. 36(4): p. 298-306.
45. Bielgorai, B., C. Meyer, L. Trakhtenbrot, H. Golan, E. Rozner, N. Amariglio, S. Izraeli, R. Marschalek, and A. Toren, Therapy-related acute myeloid leukemia with t(2;11)(q37;q23) after treatment for osteosarcoma. *Cancer Genet Cytogenet*, 2010. 203(2): p. 288-91.
46. Stark, B., G. Avrahami, R. Nirel, A. Abramov, D. Attias, A. Ballin, B. Bielgorai, Y. Burstein, H. Gavriel, R. Elhasid, J. Kapelushnik, D. Sthoeger, A. Toren, M. Wientraub, I. Yaniv, and S. Izraeli, Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies. *Br J Haematol*, 2009. 147(1): p. 113-24.
47. Salek-Ardakani, S., G. Smooha, J. de Boer, N.J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H.J. Brady, ERG is a megakaryocytic oncogene. *Cancer Res*, 2009. 69(11): p. 4665-73.
48. Meyer, C., E. Kowarz, J. Hofmann, A. Renneville, J. Zuna, J. Trka, R. Ben Abdelali, E. Macintyre, E. De Braekeleer, M. De Braekeleer, E. Delabesse, M.P. de Oliveira, H. Cave, E. Clappier, J.J. van Dongen, B.V. Balgobind, M.M. van den Heuvel-Eibrink, H.B. Beverloo, R. Panzer-Grumayer, A. Teigler-Schlegel, J. Harbott, E. Kjeldsen, S. Schnittger, U. Koehl, B. Gruhn, O. Heidenreich, L.C. Chan, S.F. Yip, M. Krzywinski, C. Eckert, A. Moricke, M. Schrappe, C.N. Alonso, B.W. Schafer, J. Krauter, D.A. Lee, U. Zur Stadt, G. Te Kronnie, R. Sutton, S. Izraeli, L. Trakhtenbrot, L. Lo Nigro, G. Tsaor, L. Fechina, T. Szczepanski, S. Strehl, D. Ilencikova, M. Molquentin, T. Burmeister, T. Dingermann, T. Klingebiel, and R. Marschalek, New insights to the MLL recombinome of acute leukemias. *Leukemia*, 2009. 23(8): p. 1490-9.
49. Malinge, S., S. Izraeli, and J.D. Crispino, Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. *Blood*, 2009. 113(12): p. 2619-28.
50. Lebanony, D., H. Benjamin, S. Gilad, M. Ezagouri, A. Dov, K. Ashkenazi, N. Gefen, S. Izraeli, G. Rechavi, H. Pass, D. Nonaka, J. Li, Y. Spector, N. Rosenfeld, A. Chajut, D. Cohen, R. Aharonov, and M. Mansukhani, 5
- Prof Shai Izraeli October 2014
- Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. *J Clin Oncol*, 2009. 27(12): p. 2030-7.
51. Inbar-Rozensal, D., A. Castiel, L. Visochek, D. Castel, F. Dantzer, S. Izraeli, and M. Cohen-Armon, A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. *Breast Cancer Res*, 2009. 11(6): p. R78.
52. Grinberg-Rashi, H., E. Ofek, M. Perelman, J. Skarda, P. Yaron, M. Hajduch, J. Jacob-Hirsch, N. Amariglio, M. Krupsky, D.A. Simansky, Z. Ram, R. Pfeffer, I. Galemter, D.M. Steinberg, I. Ben-Dov, G. Rechavi, and S. Izraeli, The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. *Clin Cancer Res*, 2009. 15(5): p. 1755-61.
53. Ganmore, I., G. Smooha, and S. Izraeli, Constitutional aneuploidy and cancer predisposition. *Hum Mol Genet*, 2009. 18(R1): p. R84-93.
54. Gaikwad, A., C.L. Rye, M. Devidas, N.A. Heerema, A.J. Carroll, S. Izraeli, S.E. Plon, G. Basso, A. Pession, and K.R. Rabin, Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. *Br J Haematol*, 2009. 144(6): p. 930-2.
55. Strehl, S., K. Nebral, M. Konig, J. Harbott, H. Strobl, R. Ratei, S. Struski, B. Bielgorai, M. Lessard, M. Zimmermann, O.A. Haas, and S. Izraeli, ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia

Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations. *Clin Cancer Res*, 2008. 14(4): p. 977-83.

56. Lo, K.C., J. Chalker, S. Strehl, M. Neat, O. Smith, N. Dastugue, L. Kearney, S. Izraeli, H. Kempfski, and J.K. Cowell, Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome. *Br J Haematol*, 2008. 142(6): p. 934-45.

57. Izraeli, S., Trisomy 21 tilts the balance. *Blood*, 2008. 112(12): p. 4361-2.

58. Golan, H., B. Bielorai, D. Grebler, S. Izraeli, G. Rechavi, and A. Toren, Integration of a palliative and terminal care center into a comprehensive pediatric oncology department. *Pediatr Blood Cancer*, 2008. 50(5): p. 949-55.

59. Fronkova, E., E. Mejstrikova, S. Avigad, K.W. Chik, L. Castillo, S. Manor, L. Reznickova, T. Valova, K. Zdrahalova, O. Hrusak, Y. Jabali, M. Schrappe, V. Conter, S. Izraeli, C.K. Li, B. Stark, J. Sary, and J. Trka, Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? *Leukemia*, 2008. 22(5): p. 989-97.

60. Forestier, E., S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C.J. Harrison, A. Teigler-Schlegel, and B. Johansson, Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. *Blood*, 2008. 111(3): p. 1575-83.

61. Erez, A., M. Chaussepied, A. Castiel, T. Colaizzo-Anas, P.D. Aplan, D. Ginsberg, and S. Izraeli, The mitotic checkpoint gene, SIL is regulated by E2F1. *Int J Cancer*, 2008. 123(7): p. 1721-5.

62. Dekel, B., S. Metsuyanin, A.M. Garcia, C. Quintero, M.J. Sanchez, and S. Izraeli, Organ-injury-induced reactivation of hemangioblastic precursor cells. *Leukemia*, 2008. 22(1): p. 103-13.

63. Bercovich, D., I. Ganmore, L.M. Scott, G. Wainreb, Y. Birger, A. Elimelech, C. Shochat, G. Cazzaniga, A. Biondi, G. Basso, G. Cario, M. Schrappe, M. Stanulla, S. Strehl, O.A. Haas, G. Mann, V. Binder, A. Borkhardt, H. Kempfski, J. Trka, B. Bielorai, S. Avigad, B. Stark, O. Smith, N. Dastugue, J.P. Bourquin, N.B. Tal, A.R. Green, and S. Izraeli, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet*, 2008. 372(9648): p. 1484-92.

64. Rosenberg, N., S. Lalezari, M. Landau, B. Shenkman, U. Seligsohn, and S. Izraeli, Trp207Gly in platelet glycoprotein Iba α is a novel mutation that disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndrome. *J Thromb Haemost*, 2007. 5(2): p. 378-86.

65. Maman, E., D.M. Steinberg, B. Stark, S. Izraeli, and S. Wientroub, Acute lymphoblastic leukemia in children: correlation of musculoskeletal manifestations and immunophenotypes. *J Child Orthop*, 2007. 1(1): p. 63-8.

66. Kaplinsky, C., L. Trakhtenbrot, and S. Izraeli, Could rhG-CSF induction of tetraploidy contribute to leukemogenesis in healthy donors? *Br J Haematol*, 2007. 138(4): p. 558.

67. Izraeli, S., L. Rainis, L. Hertzberg, G. Smooha, and Y. Birger, Trisomy of chromosome 21 in leukemogenesis. *Blood Cells, Molecules, and Diseases*, 2007. 39(2): p. 156-159.

68. Hertzberg, L., S. Izraeli, and E. Domany, STOP: searching for transcription factor motifs using gene expression. *Bioinformatics*, 2007. 23(14): p. 1737-43.

69. Hertzberg, L., D.R. Betts, S.C. Raimondi, B.W. Schafer, D.A. Nottelman, E. Domany, and S. Izraeli, Prediction of chromosomal aneuploidy from gene expression data. *Genes Chromosomes Cancer*, 2007. 46(1): p. 75-86.

70. Erez, A., A. Castiel, L. Trakhtenbrot, M. Perelman, E. Rosenthal, I. Goldstein, N. Stettner, A. Harmelin, H. Eldar-Finkelman, S. Campaner, I. Kirsch, and S. Izraeli, The SIL gene is essential for mitotic entry and survival of cancer cells. *Cancer Res*, 2007. 67(9): p. 4022-7.

71. Dehan, E., A. Ben-Dor, W. Liao, D. Lipson, H. Frimer, S. Riesenstein, D. Simansky, M. Krupsky, P. Yaron, E. Friedman, G. Rechavi, M. Perlman, A. Aviram-Goldring, S. Izraeli, M. Bittner, Z. Yakhini, and N. Kaminski, Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. *Lung Cancer*, 2007. 56(2): p. 175-84.

6

Prof Shai Izraeli October 2014

72. Cario, G., S. Izraeli, A. Teichert, P. Rhein, J. Skokowa, A. Moricke, M. Zimmermann, A. Schrauder, L. Karawajew, W.D. Ludwig, K. Welte, H.J. Schunemann, B. Schlegelberger, M. Schrappe, and M. Stanulla, High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. *J Clin Oncol*, 2007. 25(30): p. 4813-20.

73. Amit, M., N. Sela, H. Keren, Z. Melamed, I. Muler, N. Shomron, S. Izraeli, and G. Ast, Biased exonization of transposed elements in duplicated genes: A lesson from the TIF-IA gene. *BMC Mol*

- Biol, 2007. 8(1): p. 109.
74. Izraeli, S., Down's syndrome as a model of a pre-leukemic condition. *Haematologica*, 2006. 91(11): p. 1448-52.
75. Izraeli, S., Perspective: chromosomal aneuploidy in leukemia—lessons from down syndrome. *Hematol Oncol*, 2006. 24(1): p. 3-6.
76. Hochman, E., S. Kinston, A. Harmelin, B. Gottgens, and S. Izraeli, The SCL enhancer responds to Hedgehog signaling during hemangioblast specification. *Exp Hematol*, 2006. 34(12): p. 1643-50.
77. Hochman, E., A. Castiel, J. Jacob-Hirsch, N. Amariglio, and S. Izraeli, Molecular Pathways Regulating Pro-migratory Effects of Hedgehog Signaling. *J Biol Chem*, 2006. 281(45): p. 33860-70.
78. Haimi, M., R. Elhasid, R. Gershoni-Baruch, S. Izraeli, R.J. Wanders, and H. Mandel, Myeloid dysplasia in familial 3-methylglutaconic aciduria. *J Pediatr Hematol Oncol*, 2006. 28(2): p. 69-72.
79. Tabori, U., S. Rienstein, Y. Dromi, L. Leider-Trejo, S. Constantini, Y. Burstein, R. Dvir, N. Amariglio, A. Toren, G. Rechavi, S. Izraeli, and A. Aviram, Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas. *J Neurosurg*, 2005. 103(4 Suppl): p. 357-61.
80. Rothman, R., L. Trakhtenbrot, B. Bielora, S. Izraeli, G. Ishoev, N. Amariglio, G. Rechavi, and A. Toren, Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1. *Br J Haematol*, 2005. 129(4): p. 491-8.
81. Rainis, L., T. Toki, J.E. Pimanda, E. Rosenthal, K. Machol, S. Strehl, B. Gottgens, E. Ito, and S. Izraeli, The Proto-Oncogene ERG in Megakaryoblastic Leukemias. *Cancer Res*, 2005. 65(17): p. 7596-7602.
82. Izraeli, S., Chromosome copy number and leukemia—lessons from Down's syndrome. *Hematology*, 2005. 10 Suppl 1: p. 164-6.
83. Einav, U., Y. Tabach, G. Getz, A. Yitzhaky, U. Ozbek, N. Amariglio, S. Izraeli, G. Rechavi, and E. Domany, Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. *Oncogene*, 2005. 24(42): p. 6367-75.
84. Campaner, S., P. Kaldis, S. Izraeli, and I.R. Kirsch, Sil phosphorylation in a pin1 binding domain affects the duration of the spindle checkpoint. *Mol Cell Biol*, 2005. 25(15): p. 6660-72.
85. Somech, R., S. Izraeli, and J.S. A. Histone deacetylase inhibitors—a new tool to treat cancer. *Cancer Treat Rev*, 2004. 30(5): p. 461-72.
86. Izraeli, S. and D. Waldman, Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges. *Acta Haematol*, 2004. 112(1-2): p. 34-9.
87. Izraeli, S., Leukaemia – a developmental perspective. *Br J Haematol*, 2004. 126(1): p. 3-10.
88. Erez, A., M. Perelman, S.M. Hewitt, G. Cojocar, I. Goldberg, I. Shahar, P. Yaron, I. Muler, S. Campaner, N. Amariglio, G. Rechavi, I.R. Kirsch, M. Krupsky, N. Kaminski, and S. Izraeli, Sil overexpression in lung cancer characterizes tumors with increased mitotic activity. *Oncogene*, 2004. 23(31): p. 5371-7.
89. Elhasid, R., D. Sahar, A. Merling, Y. Zivony, A. Rotem, M. Ben-Arush, S. Izraeli, D. Bercovich, and S. Larisch, Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients. *Oncogene*, 2004. 23(32): p. 5468-75.
90. Dekel, B., E. Hochman, M.J. Sanchez, N. Maharshak, N. Amariglio, A.R. Green, and S. Izraeli, Kidney, blood, and endothelium: developmental expression of stem cell leukemia during nephrogenesis. *Kidney Int*, 2004. 65(4): p. 1162-9.
91. Rainis, L., D. Bercovich, S. Strehl, A. Teigler-Schlegel, B. Stark, J. Trka, N. Amariglio, A. Biondi, I. Muler, G. Rechavi, H. Kempinski, O.A. Haas, and S. Izraeli, Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. *Blood*, 2003. 102(3): p. 981-6.
92. Kaplinsky, C., L. Trakhtenbrot, I. Hardan, M. Reichart, M. Daniely, A. Toren, N. Amariglio, G. Rechavi, and S. Izraeli, Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. *Bone Marrow Transplant*, 2003. 32(1): p. 31-4.
93. Izraeli, S., Congenital syndromes and leukemia: clues to pathogenesis. *Rev Clin Exp Hematol*, 2003. 7(3): p. 246-60.
94. Karkera, J.D., S. Izraeli, E. Roessler, A. Dutra, I. Kirsch, and M. Muenke, The genomic structure, chromosomal localization, and analysis of SIL as a candidate gene for holoprosencephaly. *Cytogenet Genome Res*, 2002. 97(1-2): p. 62-7.

95. Izraeli, S., I. Witz, and M. Micksche, Cancer research—from bench to bedside. *Isr Med Assoc J*, 2002. 4(9): p. 746-8.
96. Izraeli, S. and G. Rechavi, Molecular medicine—an overview. *Isr Med Assoc J*, 2002. 4(8): p. 638-40.
97. Erez, A., T. Ilan, N. Amariglio, I. Muler, F. Brok-Simoni, G. Rechavi, and S. Izraeli, GLI3 is not mutated commonly in sporadic medulloblastomas. *Cancer*, 2002. 95(1): p. 28-31.
- 7
- Prof Shai Izraeli October 2014
98. Izraeli, S., L.A. Lowe, V.L. Bertness, S. Campaner, H. Hahn, I.R. Kirsch, and M.R. Kuehn, Genetic evidence that *Sil* is required for the Sonic Hedgehog response pathway. *Genesis*, 2001. 31(2): p. 72-7.
99. Izraeli, S., L.A. Lowe, V.L. Bertness, D.J. Good, D.W. Dorward, I.R. Kirsch, and M.R. Kuehn, The *SIL* gene is required for mouse embryonic axial development and left-right specification. *Nature*, 1999. 399(6737): p. 691-4.
100. Izraeli, S., T. Colaizzo-Anas, V.L. Bertness, K. Mani, P.D. Aplan, and I.R. Kirsch, Expression of the *SIL* gene is correlated with growth induction and cellular proliferation. *Cell Growth Differ*, 1997. 8(11): p. 1171-9.
101. Izraeli, S., B.U. Mueller, A. Ling, B.K. Temeck, L.L. Lewis, R. Chang, A.T. Shad, H.I. Pass, and P.A. Pizzo, Role of tissue diagnosis in pulmonary involvement in pediatric human immunodeficiency virus infection. *Pediatr Infect Dis J*, 1996. 15(2): p. 112-6.
102. Ho, P.T., K. Zimmerman, L.H. Wexler, S. Blaney, P. Jarosinski, L. Weaver-McClure, S. Izraeli, and F.M. Balis, A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. *Cancer*, 1995. 76(12): p. 2557-64.
103. Alhalel, A., I. Ziv, D. Versano, M. Ruach, M. Alkalay, S. Almog, S. Izraeli, and J. Glovinsky, Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. *Aviat Space Environ Med*, 1995. 66(11): p. 1037-40.
104. Izraeli, S., P.C. Adamson, S.M. Blaney, and F.M. Balis, Acute pancreatitis after ifosfamide therapy. *Cancer*, 1994. 74(5): p. 1627-8.
105. Izraeli, S., J.W. Janssen, O.A. Haas, J. Harbott, F. Brok-Simoni, J.U. Walther, H. Kovar, T. Henn, W.D. Ludwig, A. Reiter, and et al., Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. *Leukemia*, 1993. 7(5): p. 671-8.
106. Izraeli, S., T. Henn, H. Strobl, W.D. Ludwig, H. Kovar, O.A. Haas, J. Harbott, C.R. Bartram, H. Gadner, and T. Lion, Expression of identical *E2A/PBX1* fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. *Leukemia*, 1993. 7(12): p. 2054-6.
107. Izraeli, S., L. Ben-Sira, D. Harell, N. Naor, A. Ballin, and S. Davidson, Lactic acid as a predictor for erythrocyte transfusion in healthy preterm infants with anemia of prematurity. *J Pediatr*, 1993. 122(4): p. 629-31.
108. Baharav, A., M. Mimouni, T. Lehrman-Sagie, S. Izraeli, and S. Akselrod, Spectral analysis of heart rate in vasovagal syncope: the autonomic nervous system in vasovagal syncope. *Clin Auton Res*, 1993. 3(4): p. 261-9.
109. Ziv, I., D. Versano, M. Ruach, S. Izraeli, S. Almog, A. Alhalel, M. Alkalay, S. Menahem, and Z. Tochner, Prevention of peripheral side-effects of transdermal hyoscine by adjunctive therapy with low dosage of pyridostigmine. *Br J Clin Pharmacol*, 1992. 33(5): p. 507-10.
110. Lion, T., S. Izraeli, T. Henn, A. Gaiger, W. Mor, and H. Gadner, Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. *Leukemia*, 1992. 6(6): p. 495-9.
111. Izraeli, S., A. Metzker, G. Horev, D. Karmi, P. Merlob, and Z. Farfel, Albright hereditary osteodystrophy with hypothyroidism, normocalcemia, and normal Gs protein activity: a family presenting with congenital osteoma cutis. *Am J Med Genet*, 1992. 43(4): p. 764-7.
112. Izraeli, S., H. Kovar, H. Gadner, and T. Lion, Unexpected heterogeneity in *E2A/PBX1* fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia. *Blood*, 1992. 80(6): p. 1413-7.
113. Izraeli, S., E. Freud, C. Mor, A. Litwin, M. Zer, and P. Merlob, Neonatal intestinal perforation due to congenital defects in the intestinal muscularis. *Eur J Pediatr*, 1992. 151(4): p. 300-3.
114. Alkalay, M., S. Izraeli, R. Wallach-Kapon, Z. Tochner, Y. Benjamini, and S. Akselrod, Paradoxical

pharmacodynamic effect of atropine on parasympathetic control: a study by spectral analysis of heart rate fluctuations. *Clin Pharmacol Ther*, 1992. 52(5): p. 518-27.

115. Alcalay, M., M. Arad, E. Krasner, S. Izraeli, I. Ziv, J. Atsmon, and I. Bruderman, Pediatric protective respiratory device: assessment of physiologic compatibility. *Am J Dis Child*, 1992. 146(3): p. 275-8.

116. Izraeli, S., Z. Samra, L. Sirota, P. Merlob, and S. Davidson, Genital mycoplasmas in preterm infants: prevalence and clinical significance. *Eur J Pediatr*, 1991. 150(11): p. 804-7.

117. Izraeli, S., C. Pfeleiderer, and T. Lion, Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood. *Nucleic Acids Res*, 1991. 19(21): p. 6051.

118. Izraeli, S. and T. Lion, Multiprimer-PCR for screening of genetic abnormalities in acute lymphoblastic leukaemia. *Br J Haematol*, 1991. 79(4): p. 645-7.

119. Izraeli, S., M. Alcalay, Y. Benjamini, R. Wallach-Kapon, Z. Tochner, and S. Akselrod, Modulation of the dose-dependent effects of atropine by low-dose pyridostigmine: quantification by spectral analysis of heart rate fluctuations in healthy human beings. *Pharmacol Biochem Behav*, 1991. 39(3): p. 613-7.

120. Alcalay, M., S. Izraeli, R. Wallach-Kapon, Z. Tochner, Y. Benjamini, and S. Akselrod, Pharmacological modulation of vagal cardiac control measured by heart rate power spectrum: a possible bioequivalent probe. *Neurosci Biobehav Rev*, 1991. 15(1): p. 51-5.

121. Izraeli, S., A. Rachmel, Y. Frishberg, A. Erman, B. Flasterstein, M. Nitzan, and G. Boner, Transient renal acidification defect during acute infantile diarrhea: the role of urinary sodium. *J Pediatr*, 1990. 117(5): p. 711-6.

8

Prof Shai Izraeli October 2014

122. Izraeli, S., A. Elhalel, M. Graif, M. Alcalay, I. Ziv, M. Glikson, Y. Glovinsky, and Z. Tochner, Optimal needle length of automatic injectors. *Crit Care Med*, 1990. 18(5): p. 547-8.

123. Izraeli, S., D. Avgar, S. Almog, I. Shochat, Z. Tochner, A. Tamir, and J. Ribak, The effect of repeated doses of 30 mg pyridostigmine bromide on pilot performance in an A-4 flight simulator. *Aviat Space Environ Med*, 1990. 61(5): p. 430-2.

124. Izraeli, S., A. Rachmel, and M. Nitzan, [Vestibular dysfunction and deafness complicating mumps parotitis]. *Harefuah*, 1989. 117(9): p. 243-4.

125. Izraeli, S., B. Flasterstein, R. Shamir, A. Rachmel, M. Nitzan, M. Drucker, and Z. Samra, *Branhamella catarrhalis* as a cause of suppurative arthritis. *Pediatr Infect Dis J*, 1989. 8(4): p. 256-7.

126. Izraeli, S., A. Israeli, and Y. Danon, [Pharmacological treatment of cyanide poisoning]. *Harefuah*, 1988. 114(7): p. 338-42.

127. Izraeli, S., D. Avgar, M. Glikson, I. Shochat, Y. Glovinsky, and J. Ribak, Determination of the time of useful consciousness (TUC) in repeated exposures to simulated altitude of 25,000 ft (7,620 m). *Aviat Space Environ Med*, 1988. 59(11 Pt 1): p. 1103-5.

128. Izraeli, S., M. Glikson, and I. Ziv, Diagnosis of organophosphate poisoning. *West J Med*, 1986. 145(5): p. 698.

129. Shapiro, M., E. Simchen, S. Izraeli, and T.G. Sacks, A multivariate analysis of risk factors for acquiring bacteriuria in patients with indwelling urinary catheters for longer than 24 hours. *Infect Control*, 1984. 5(11): p. 525-32.

Chapters in Books

- M E. Gatt, D. Ben-Yehuda, S. Izraeli . Lymphoid Leukemias. In RR. Rich, TA. Fleisher, BD. Schwartz, WT. Shearer, W. Strober (eds.), *Clinical Immunology Principles and Practice*. 3rd Edition , Mosby St Lewis Missouri. Chapter 76, pp 1131-1150, 2008

- S. Izraeli, G. Rechavi. Childhood Cancer – an introduction. In Krietler S, Weyl Ben Arush M (eds.) *Psycho-Social aspects of pediatric oncology*. Wiley. 2012 pp.3-9

- H Kovar, S. Izraeli. The Biology of Cancer in Children. In M Stevens, H.N. Caron, A Biondi, (Eds) *Cancer in Children: Clinical Management 2nd Edition*, Oxford University Press, Oxford 2012

Projects

Patents:

PHARMACEUTICAL COMPOSITION AND METHOD FOR REGULA

Memberships

Other Experience and Professional Memberships

2014-present

Elected Member of the Board of the European Hematology Association, Chair of the Scientific Program Committee of the 2017 EHA congress.

2014-present

Editorial Board Blood

2005 - 2010

Chair, Biology and Diagnosis Committee, iBFM Study group on pediatric hematological malignancies

2011-present

Editorial Board Cellular and Molecular Life Sciences

2002 - present

Co-Chair , Israel National Study , Childhood ALL

2004 – present

Chair (alternate) Study Section of Cancer, Chief Scientist, Israel Health Ministry

2006-2013

Member several committees European Hematology Association

2006 - present

Tel Aviv University Cancer Biology Center, scientific and management committee

2010 – present

Head, MD-PhD program, Sackler Medical School, Tel Aviv University

2008-present

Member Israel National Council on Oncology

2005 - present

Member of “Ponte di Legno”; international group on childhood acute lymphoblastic leukemias

2000 - present

American Society of Hematology

2007 - present

European Hematology Association (Scientific Committee and Board member)

2000 - present

Israel Society of Pediatric Hemato-Oncology

2000 - present

Israel Society of Thrombosis and Hematology

Honors

1999

NIH Fellows Award for Research Excellence

2002

Hannover Award for Leukemia and Lymphoma Research.

2002, 2006

Excellence Award, Israel Cancer Association

2006

Owen Rennert’s Endowed Lecture in Pediatric Oncology, Georgetown University

2006

TEVA inc Founder Award for Research Excellence

2008, 2009, 2013

Moran Prize for Research Excellence in Pediatrics, Tel – Aviv University

2008

Presidential Award – British Society of Hematology Annual Scientific Meeting

Other Relevant Information

C. Competitive Grants

Past and/or present competitive grants from the following agencies:

USA: National Institutes of Health, Department of Defense, Israel Cancer Research Foundation (New York), Waxman Cancer Research Foundation (New York), William Lawrence and Blanche Hughes Foundation (University of Southern California), Diamond Blackfan Anemia Foundation.

Europe: Children with Cancer (UK), EU FP-7 ERA-NET, Swiss Bridge Foundation (CH),

Israel: Israel Science Foundation, US-Israel Binational Science Foundation, German Israel Foundation, Israel Ministry of Science, Israel Ministry of Health, Israel Ministry of Economics, Israel Cancer Association,